L LIGAND PHARMACEUTICALS
$205.14
| Market Cap | $4.09B |
| P/E Ratio | 33.41 |
| Forward P/E | 21.16 |
| Dividend Yield | — |
| Beta | 1.03 |
| 52W Range | $93.58 - $212.49 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 112 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Sale | 159 | $204.26 | $32.48K | 01 Apr 2026 | 01 Apr 2026 |
| KOZARICH JOHN W | Sale | 43 | $202.91 | $8.73K | 01 Apr 2026 | 01 Apr 2026 |
| KOZARICH JOHN W | Sale | 79 | $202.42 | $15.99K | 01 Apr 2026 | 01 Apr 2026 |
| KOZARICH JOHN W | Sale | 40 | $201.24 | $8.05K | 01 Apr 2026 | 01 Apr 2026 |
| KOZARICH JOHN W | Sale | 146 | $199.97 | $29.20K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 337 | $204.50 | $68.92K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 963 | $203.22 | $195.70K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 700 | $201.90 | $141.33K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 1,238 | $200.94 | $248.77K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 1,302 | $199.72 | $260.04K | 01 Apr 2026 | 01 Apr 2026 |
| Reardon AndrewCLO & Secretary | Sale | 460 | $198.85 | $91.47K | 01 Apr 2026 | 01 Apr 2026 |
| Sabba Stephen L | Sale | 1,000 | $207.87 | $207.87K | 23 Mar 2026 | 23 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 3,057 | $225.00 | $687.83K | 11 Mar 2026 | 13 Mar 2026 |
| John L LamattinaDirector | Sale | 2,161 | $200.76 | $433.84K | 06 Mar 2026 | 31 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 1,446 | $208.12 | $300.94K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 612 | $207.01 | $126.69K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 460 | $205.18 | $94.38K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 300 | $201.70 | $60.51K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 1,588 | $206.89 | $328.54K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 1,457 | $205.79 | $299.84K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 668 | $203.63 | $136.02K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 698 | $201.09 | $140.36K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 699 | $198.71 | $138.89K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 1,142 | $208.87 | $238.53K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 340 | $206.37 | $70.16K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 200 | $204.17 | $40.83K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 93 | $200.62 | $18.66K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 207 | $199.96 | $41.39K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 100 | $199.01 | $19.90K | 04 Mar 2026 | 06 Mar 2026 |
| Reardon AndrewCLO & Secretary | Sale | 100 | $197.70 | $19.77K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 3,413 | $208.80 | $712.62K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 2,457 | $207.91 | $510.82K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 743 | $204.74 | $152.13K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 697 | $202.79 | $141.34K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 950 | $201.73 | $191.64K | 04 Mar 2026 | 06 Mar 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 53 | $200.08 | $10.60K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 1,446 | $208.12 | $300.94K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 93 | $200.62 | $18.66K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 100 | $199.01 | $19.90K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 100 | $197.70 | $19.77K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 1,142 | $208.87 | $238.53K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 612 | $207.01 | $126.69K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 207 | $199.96 | $41.39K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 668 | $203.63 | $136.02K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 53 | $200.08 | $10.60K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 699 | $198.71 | $138.89K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 1,457 | $205.79 | $299.84K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 950 | $201.73 | $191.64K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 460 | $205.18 | $94.38K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 300 | $201.70 | $60.51K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 340 | $206.37 | $70.16K | 04 Mar 2026 | 06 Mar 2026 |
| Andrew ReardonCLO & Secretary | Sale | 200 | $204.17 | $40.83K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 3,413 | $208.80 | $712.62K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 1,588 | $206.89 | $328.54K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 743 | $204.74 | $152.13K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 698 | $201.09 | $140.36K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 2,457 | $207.91 | $510.82K | 04 Mar 2026 | 06 Mar 2026 |
| Octavio EspinozaChief Financial Officer | Sale | 697 | $202.79 | $141.34K | 04 Mar 2026 | 06 Mar 2026 |
| Sabba Stephen L | Sale | 2,034 | $201.50 | $409.85K | 03 Mar 2026 | 05 Mar 2026 |
| KOZARICH JOHN W | Sale | 50 | $202.54 | $10.13K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 41 | $200.40 | $8.22K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 204 | $199.69 | $40.74K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 42 | $203.57 | $8.55K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 83 | $201.65 | $16.74K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 47 | $197.14 | $9.27K | 02 Mar 2026 | 04 Mar 2026 |
| KOZARICH JOHN W | Sale | 381 | $196.36 | $74.81K | 02 Feb 2026 | 04 Feb 2026 |
| KOZARICH JOHN W | Sale | 23 | $195.61 | $4.50K | 02 Feb 2026 | 04 Feb 2026 |
| KOZARICH JOHN W | Sale | 23 | $197.20 | $4.54K | 02 Feb 2026 | 04 Feb 2026 |
| KOZARICH JOHN W | Sale | 1 | $192.18 | $192.18 | 02 Feb 2026 | 04 Feb 2026 |
| KOZARICH JOHN W | Sale | 39 | $191.00 | $7.45K | 02 Feb 2026 | 04 Feb 2026 |
| John W KozarichDirector | Sale | 23 | $197.20 | $4.54K | 02 Feb 2026 | 04 Feb 2026 |
| John W KozarichDirector | Sale | 1 | $192.18 | $192.18 | 02 Feb 2026 | 04 Feb 2026 |
| John W KozarichDirector | Sale | 39 | $191.00 | $7.45K | 02 Feb 2026 | 04 Feb 2026 |
| John W KozarichDirector | Sale | 381 | $196.36 | $74.81K | 02 Feb 2026 | 04 Feb 2026 |
| John W KozarichDirector | Sale | 23 | $195.61 | $4.50K | 02 Feb 2026 | 04 Feb 2026 |
| KOZARICH JOHN W | Sale | 46 | $192.40 | $8.85K | 02 Jan 2026 | 06 Jan 2026 |
| KOZARICH JOHN W | Sale | 207 | $190.27 | $39.39K | 02 Jan 2026 | 06 Jan 2026 |
| KOZARICH JOHN W | Sale | 102 | $188.96 | $19.27K | 02 Jan 2026 | 06 Jan 2026 |
| KOZARICH JOHN W | Sale | 91 | $187.95 | $17.10K | 02 Jan 2026 | 06 Jan 2026 |
| KOZARICH JOHN W | Sale | 21 | $186.59 | $3.92K | 02 Jan 2026 | 06 Jan 2026 |
| John W KozarichDirector | Sale | 46 | $192.40 | $8.85K | 02 Jan 2026 | 06 Jan 2026 |
| John W KozarichDirector | Sale | 207 | $190.27 | $39.39K | 02 Jan 2026 | 06 Jan 2026 |
| John W KozarichDirector | Sale | 102 | $188.96 | $19.27K | 02 Jan 2026 | 06 Jan 2026 |
| John W KozarichDirector | Sale | 91 | $187.95 | $17.10K | 02 Jan 2026 | 06 Jan 2026 |
| John W KozarichDirector | Sale | 21 | $186.59 | $3.92K | 02 Jan 2026 | 06 Jan 2026 |
| Espinoza OctavioChief Financial Officer | Sale | 1,804 | $188.31 | $339.71K | 12 Dec 2025 | 16 Dec 2025 |
| KOZARICH JOHN W | Sale | 30 | $200.02 | $6.00K | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 23 | $199.22 | $4.58K | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 4 | $196.35 | $785.38 | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 92 | $197.72 | $18.19K | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 47 | $195.80 | $9.20K | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 179 | $194.76 | $34.86K | 01 Dec 2025 | 03 Dec 2025 |
| KOZARICH JOHN W | Sale | 92 | $193.86 | $17.83K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 92 | $197.72 | $18.19K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 179 | $194.76 | $34.86K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 92 | $193.86 | $17.83K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 30 | $200.02 | $6.00K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 23 | $199.22 | $4.58K | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 4 | $196.35 | $785.38 | 01 Dec 2025 | 03 Dec 2025 |
| John W KozarichDirector | Sale | 47 | $195.80 | $9.20K | 01 Dec 2025 | 03 Dec 2025 |
| LAMATTINA JOHN L | Sale | 2,145 | $205.45 | $440.69K | 07 Nov 2025 | 12 Nov 2025 |
| Gray Nancy Ryan | Sale | 3,015 | $205.45 | $619.43K | 07 Nov 2025 | 12 Nov 2025 |
| Gray Nancy Ryan | Sale | 3,556 | $205.45 | $730.58K | 07 Nov 2025 | 12 Nov 2025 |
| LAMATTINA JOHN L | Sale | 2,034 | $205.45 | $417.89K | 07 Nov 2025 | 12 Nov 2025 |
| KOZARICH JOHN W | Sale | 127 | $192.38 | $24.43K | 03 Nov 2025 | 05 Nov 2025 |
| KOZARICH JOHN W | Sale | 207 | $191.25 | $39.59K | 03 Nov 2025 | 05 Nov 2025 |
| KOZARICH JOHN W | Sale | 49 | $190.26 | $9.32K | 03 Nov 2025 | 05 Nov 2025 |
| KOZARICH JOHN W | Sale | 84 | $189.00 | $15.88K | 03 Nov 2025 | 05 Nov 2025 |
| John W KozarichDirector | Sale | 127 | $192.38 | $24.43K | 03 Nov 2025 | 05 Nov 2025 |
| John W KozarichDirector | Sale | 207 | $191.25 | $39.59K | 03 Nov 2025 | 05 Nov 2025 |
| John W KozarichDirector | Sale | 49 | $190.26 | $9.32K | 03 Nov 2025 | 05 Nov 2025 |
| John W KozarichDirector | Sale | 84 | $189.00 | $15.88K | 03 Nov 2025 | 05 Nov 2025 |
Frequently Asked Questions
What is LGND stock price today?
LIGAND PHARMACEUTICALS (LGND) is currently trading at $205.14. The stock has a 52-week range of $93.58 to $212.49 and a market capitalization of $4.09B.
Is LGND a good stock to buy in 2026?
LIGAND PHARMACEUTICALS has a P/E ratio of 33.4 (forward P/E: 21.2), a dividend yield of none, and 1-year performance of +87.5%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling LGND stock?
There have been 112 insider transactions for LGND in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has LGND stock performed over the past year?
LIGAND PHARMACEUTICALS (LGND) has returned +87.5% over the past 12 months. The stock traded between $93.58 and $212.49 during this period, and is currently at $205.14.
Which hedge funds own LGND (LIGAND PHARMACEUTICALS)?
0 tracked hedge funds currently hold LGND in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is LGND's market cap and valuation?
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of $4.09B. The trailing P/E ratio is 33.4 and forward P/E is 21.2. The stock is classified in the Healthcare sector.
What is LGND's revenue and profitability?
LIGAND PHARMACEUTICALS reported revenue of $268.09M with net income of $124.45M and a profit margin of 0.46%. The stock has a beta of 1.03.
What sector is LGND in and who are its biggest institutional holders?
LIGAND PHARMACEUTICALS (LGND) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.